{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for mafodotin in Any Name (approximate match)
Showing 1 - 8 of 8 results
Status:
Investigational
Source:
USAN:MAFODOTIN [USAN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Mafodotin (mc-MMAF) is a hydrophilic non-cleavable antimicrotubule and antimitotic agent, monomethyl auristatin F (MMAF) derivative, having a maleimidocaproyl linker (mc linker), which is ready to conjugate to an antibody or other proteins or biopolymers. Antibody-drug conjugates having mafodotin such as Depatuxizumab mafodotin and Belantamab mafodotin have undergone clinical trials for the treatment of neoplasms.
Status:
Investigational
Source:
NCT02573324: Phase 3 Interventional Completed Glioblastoma
(2015)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01786096: Phase 1 Interventional Completed Burkitt Lymphoma
(2013)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01015911: Phase 1 Interventional Completed Carcinoma, Renal Cell
(2009)
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
BLA761158
(2020)
Source URL:
First approved in 2020
Source:
BLA761158
Source URL:
Class:
PROTEIN
Status:
Other
Class:
CONCEPT
